Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer
•Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is clinically challenging.•Methods to better select patients for re-RT is of paramount importance.•Proton therapy re-RT of rHNC affords good local control and an acceptable toxicity profile.•Distant failures are common, and are associ...
Saved in:
Published in | Oral oncology Vol. 154; p. 106875 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is clinically challenging.•Methods to better select patients for re-RT is of paramount importance.•Proton therapy re-RT of rHNC affords good local control and an acceptable toxicity profile.•Distant failures are common, and are associated with TP53, NOTCH4, and ARID1B somatic mutations.•Validation may provide rationale for inclusion of genomic alterations in the decision process.
Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for recurrent HNC, and report genomic alterations associated with patterns of failure.
We performed a retrospective analysis of rHNC patients treated with PT. Outcomes were estimated using the Kaplan-Meier method. Univariate (UVA) and multivariate analyses (MVA) were performed to assess multiple patient factors. Next-generation sequencing and genomic analyses were performed on available samples.
Eighty-nine patients treated with PBS-PT for rHNC with a median follow-up of 12 mo (0–71 mo) were included. The 1- and 2-y local control (LC) rates were 80.8 % (95 % CI: 70.8–90.8) and 66.2 % (95 % CI: 50.7–81.7), and 1- and 2-y distant metastasis-free survival (DMFS) were 41.0 % (95 % CI: 30.0–52.0) and 26.3 % (95 % CI: 15.7–36.9). The median overall survival (OS) was 13 mo (95 % CI: 9.3–16.7). On UVA and MVA, smaller gross tumor volume (GTV) was associated with improved OS (HR 1.002, P = 0.004), DMFS (HR 1.002, P = 0.004), and PFS (HR 1.002, P = 0.014). There were 35 late Gr3 + toxicity events (30.3 %). Patients with higher candidate gene-specific mutation burden (genes with [OR] > 2, P < 0.05) had inferior PFS. TP53, NOTCH4, and ARID1B mutations were associated with inferior DMFS (OR > 2, P < 0.05).
PBS-PT is effective at achieving LC for rHNC with favorable toxicity. Distant metastases are common, and associated with TP53, NOTCH4, and ARID1B mutations. Inclusion of genomic alterations in the clinical decision process may be warranted. |
---|---|
AbstractList | INTRODUCTIONRe-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for recurrent HNC, and report genomic alterations associated with patterns of failure.MATERIALS & METHODSWe performed a retrospective analysis of rHNC patients treated with PT. Outcomes were estimated using the Kaplan-Meier method. Univariate (UVA) and multivariate analyses (MVA) were performed to assess multiple patient factors. Next-generation sequencing and genomic analyses were performed on available samples.RESULTSEighty-nine patients treated with PBS-PT for rHNC with a median follow-up of 12 mo (0-71 mo) were included. The 1- and 2-y local control (LC) rates were 80.8 % (95 % CI: 70.8-90.8) and 66.2 % (95 % CI: 50.7-81.7), and 1- and 2-y distant metastasis-free survival (DMFS) were 41.0 % (95 % CI: 30.0-52.0) and 26.3 % (95 % CI: 15.7-36.9). The median overall survival (OS) was 13 mo (95 % CI: 9.3-16.7). On UVA and MVA, smaller gross tumor volume (GTV) was associated with improved OS (HR 1.002, P = 0.004), DMFS (HR 1.002, P = 0.004), and PFS (HR 1.002, P = 0.014). There were 35 late Gr3 + toxicity events (30.3 %). Patients with higher candidate gene-specific mutation burden (genes with [OR] > 2, P < 0.05) had inferior PFS. TP53, NOTCH4, and ARID1B mutations were associated with inferior DMFS (OR > 2, P < 0.05).CONCLUSIONSPBS-PT is effective at achieving LC for rHNC with favorable toxicity. Distant metastases are common, and associated with TP53, NOTCH4, and ARID1B mutations. Inclusion of genomic alterations in the clinical decision process may be warranted. •Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is clinically challenging.•Methods to better select patients for re-RT is of paramount importance.•Proton therapy re-RT of rHNC affords good local control and an acceptable toxicity profile.•Distant failures are common, and are associated with TP53, NOTCH4, and ARID1B somatic mutations.•Validation may provide rationale for inclusion of genomic alterations in the decision process. Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for recurrent HNC, and report genomic alterations associated with patterns of failure. We performed a retrospective analysis of rHNC patients treated with PT. Outcomes were estimated using the Kaplan-Meier method. Univariate (UVA) and multivariate analyses (MVA) were performed to assess multiple patient factors. Next-generation sequencing and genomic analyses were performed on available samples. Eighty-nine patients treated with PBS-PT for rHNC with a median follow-up of 12 mo (0–71 mo) were included. The 1- and 2-y local control (LC) rates were 80.8 % (95 % CI: 70.8–90.8) and 66.2 % (95 % CI: 50.7–81.7), and 1- and 2-y distant metastasis-free survival (DMFS) were 41.0 % (95 % CI: 30.0–52.0) and 26.3 % (95 % CI: 15.7–36.9). The median overall survival (OS) was 13 mo (95 % CI: 9.3–16.7). On UVA and MVA, smaller gross tumor volume (GTV) was associated with improved OS (HR 1.002, P = 0.004), DMFS (HR 1.002, P = 0.004), and PFS (HR 1.002, P = 0.014). There were 35 late Gr3 + toxicity events (30.3 %). Patients with higher candidate gene-specific mutation burden (genes with [OR] > 2, P < 0.05) had inferior PFS. TP53, NOTCH4, and ARID1B mutations were associated with inferior DMFS (OR > 2, P < 0.05). PBS-PT is effective at achieving LC for rHNC with favorable toxicity. Distant metastases are common, and associated with TP53, NOTCH4, and ARID1B mutations. Inclusion of genomic alterations in the clinical decision process may be warranted. Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for recurrent HNC, and report genomic alterations associated with patterns of failure. We performed a retrospective analysis of rHNC patients treated with PT. Outcomes were estimated using the Kaplan-Meier method. Univariate (UVA) and multivariate analyses (MVA) were performed to assess multiple patient factors. Next-generation sequencing and genomic analyses were performed on available samples. Eighty-nine patients treated with PBS-PT for rHNC with a median follow-up of 12 mo (0-71 mo) were included. The 1- and 2-y local control (LC) rates were 80.8 % (95 % CI: 70.8-90.8) and 66.2 % (95 % CI: 50.7-81.7), and 1- and 2-y distant metastasis-free survival (DMFS) were 41.0 % (95 % CI: 30.0-52.0) and 26.3 % (95 % CI: 15.7-36.9). The median overall survival (OS) was 13 mo (95 % CI: 9.3-16.7). On UVA and MVA, smaller gross tumor volume (GTV) was associated with improved OS (HR 1.002, P = 0.004), DMFS (HR 1.002, P = 0.004), and PFS (HR 1.002, P = 0.014). There were 35 late Gr3 + toxicity events (30.3 %). Patients with higher candidate gene-specific mutation burden (genes with [OR] > 2, P < 0.05) had inferior PFS. TP53, NOTCH4, and ARID1B mutations were associated with inferior DMFS (OR > 2, P < 0.05). PBS-PT is effective at achieving LC for rHNC with favorable toxicity. Distant metastases are common, and associated with TP53, NOTCH4, and ARID1B mutations. Inclusion of genomic alterations in the clinical decision process may be warranted. |
ArticleNumber | 106875 |
Author | Krc, Rebecca Mehra, Ranee Tran, Phuoc Papadimitriou, John C. Shetty, Amol Song, Yang Wolf, Jeffrey Ferris, Matthew Regine, William Molitoris, Jason Taylor, Rodney Mendes, William Hatten, Kyle Sun, Kai Bentzen, Soren Witek, Matthew |
Author_xml | – sequence: 1 givenname: Rebecca orcidid: 0000-0002-4164-0392 surname: Krc fullname: Krc, Rebecca organization: Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD, USA – sequence: 2 givenname: William surname: Mendes fullname: Mendes, William organization: Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD, USA – sequence: 3 givenname: Jason surname: Molitoris fullname: Molitoris, Jason organization: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 4 givenname: Matthew surname: Ferris fullname: Ferris, Matthew organization: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 5 givenname: Yang surname: Song fullname: Song, Yang organization: Institute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 6 givenname: Amol surname: Shetty fullname: Shetty, Amol organization: Institute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 7 givenname: Ranee surname: Mehra fullname: Mehra, Ranee organization: University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 8 givenname: John C. surname: Papadimitriou fullname: Papadimitriou, John C. organization: Department of Pathology/Biorepository Shared Service, University of Maryland Baltimore, Baltimore, MD, USA – sequence: 9 givenname: Kyle surname: Hatten fullname: Hatten, Kyle organization: Department of Otorhinolaryngology – Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 10 givenname: Rodney surname: Taylor fullname: Taylor, Rodney organization: Department of Otorhinolaryngology – Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 11 givenname: Jeffrey surname: Wolf fullname: Wolf, Jeffrey organization: Department of Otorhinolaryngology – Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 12 givenname: Kai surname: Sun fullname: Sun, Kai email: ksun@som.umaryland.edu organization: Division of Biostatistics and Bioinformatics, University of Maryland Greenbaum Cancer Center, and Department of Epidemiology and Public Health, Baltimore, MD, USA – sequence: 13 givenname: Soren surname: Bentzen fullname: Bentzen, Soren email: sbentzen@som.umaryland.edu organization: Division of Biostatistics and Bioinformatics, University of Maryland Greenbaum Cancer Center, and Department of Epidemiology and Public Health, Baltimore, MD, USA – sequence: 14 givenname: William surname: Regine fullname: Regine, William organization: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 15 givenname: Phuoc surname: Tran fullname: Tran, Phuoc email: phuoc.tran@umm.edu organization: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 16 givenname: Matthew surname: Witek fullname: Witek, Matthew email: mattewitek@gmail.com organization: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38824813$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkUtv1DAQxy3Uij7gKyCLE5csdhzHzhGVp1SJHtqz5ce46yWxg-2A9tvjskXiNK_fjGbmf4XOYoqA0FtKdpTQ8f1hl7KeU7RpTo_HXU_6oRVGKfgLdEmlmDrCJ3bWfDbKTjLBL9BVKQdCCKecvEQXTMp-kJRdovkup5oirnvIej3iDF3IWbuga2jptFWbFihYR4cfIaYlWDy3oFi9Ak4erw2EWAv-Heq-tdst5xbjPWj3tyuC_YGtjhbyK3Tu9Vzg9bO9Rg-fP93ffO1uv3_5dvPhtrOM0toNvufMGeZB6NEL7TUw4iU1k3c918I40w898YabaWKOAHfcGyHtNAlDrGDX6N1p7prTzw1KVUsoFua2OKStKEbGgQ6MD6Shb57RzSzg1JrDovNR_ftQAz6eAGgL_wqQVbHtYAsutGOrcikoStSTMOqg_hdGPQmjTsKwP8tHiNg |
CitedBy_id | crossref_primary_10_1016_j_oraloncology_2024_106912 crossref_primary_10_1016_j_oraloncology_2024_106899 crossref_primary_10_1016_j_oraloncology_2024_106915 |
ContentType | Journal Article |
Copyright | 2024 The Authors Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Copyright_xml | – notice: 2024 The Authors – notice: Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.oraloncology.2024.106875 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Dentistry |
EISSN | 1879-0593 |
EndPage | 106875 |
ExternalDocumentID | 38824813 S1368837524001933 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29N 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6I. 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAWTL AAXUO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K X7M XPP Z5R ZA5 ZGI ~G- AAXKI AFJKZ CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c311t-4f253db3fe7a6f7afae30f81b9fd25a7bdb2420fb5b993d0e5d5fb78c997b0c73 |
IEDL.DBID | .~1 |
ISSN | 1368-8375 |
IngestDate | Thu Dec 05 23:27:31 EST 2024 Sat Nov 02 12:28:18 EDT 2024 Tue Jun 18 08:50:43 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Recurrent head and neck cancer Proton therapy Pencil beam scanning Toxicity Genomics |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c311t-4f253db3fe7a6f7afae30f81b9fd25a7bdb2420fb5b993d0e5d5fb78c997b0c73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4164-0392 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1368837524001933 |
PMID | 38824813 |
PQID | 3064143540 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_3064143540 pubmed_primary_38824813 elsevier_sciencedirect_doi_10_1016_j_oraloncology_2024_106875 |
PublicationCentury | 2000 |
PublicationDate | July 2024 2024-Jul 20240701 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Oral oncology |
PublicationTitleAlternate | Oral Oncol |
PublicationYear | 2024 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Janot, de Raucourt, Benhamou (b0070) 2008; 26 McDonald, Zolali-Meybodi, Lehnert (b0055) 2016; 96 Romesser, Cahlon, Scher (b0050) 2016; 95 Hamoir, Schmitz, Suarez (b0085) 2018; 10 Strojan, Corry, Eisbruch (b0020) 2015; 37 Ward, Koyfman, Bakst (b0030) 2022; 113 Lee, Woods, Mahfouz (b0060) 2023; 6 Ferris, Blumenschein, Fayette (b0125) 2016; 375 Riaz, Hong, Sherman (b0065) 2014; 111 Vargo, Ward, Caudell (b0025) 2018; 100 Yamazaki, Masui, Suzuki (b0105) 2022; 21 Burtness, Harrington, Greil (b0135) 2019; 394 Vargo, Heron, Ferris (b0150) 2012; 104 Wong, Heron, Stenson, Ling, Vargo (b0095) 2016; 36 Rivera, García-Castaño, Vega, Vega-Villegas, Gutiérrez-Sanz (b0130) 2009; 9 Bhalavat, Pareek, Chandra (b0110) 2018; 10 Li, Jiang, Qiu, Sun, Wang (b0080) 2022; 20 Chen, Ma, Ye, Hou, Xie, Bai (b0075) 2013; 8 Narayana, Cohen, Zaider (b0100) 2007; 6 Harishankar, Prince, Mohan, Krishnan, Devi (b0145) 2016 Melariri, Els, Oyedele (b0120) 2023 Gamez, Patel, McGee (b0040) 2021; 8 Hartl, Guerlain, Gorphe (b0090) 2023; 15 Gillison, Trotti, Harris (b0005) 2019; 393 Gordon, Smyk, Gulidov (b0045) 2021; 13 Forastiere, Zhang, Weber (b0010) 2013; 31 Morton, Rugman, Dorman (b0115) 1985; 15 Mehanna, Kong, Ahmed (b0035) 2016; 130 Nguyen-Tan, Zhang, Ang (b0015) 2014; 32 |
References_xml | – volume: 21 start-page: 341 year: 2022 end-page: 346 ident: b0105 article-title: Reirradiation for recurrent head and neck carcinoma using high-dose-rate brachytherapy: a multi-institutional study publication-title: Brachytherapy contributor: fullname: Suzuki – volume: 96 year: 2016 ident: b0055 article-title: Reirradiation of recurrent and second primary head and neck cancer with proton therapy publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Lehnert – volume: 36 year: 2016 ident: b0095 article-title: Locoregional recurrent or second primary head and neck cancer: management strategies and challenges publication-title: Am Soc Clin Oncol Educ Book contributor: fullname: Vargo – volume: 15 year: 2023 ident: b0090 article-title: Review of outcomes after salvage surgery for recurrent squamous cell carcinoma of the head and neck publication-title: Cancers (Basel) contributor: fullname: Gorphe – volume: 375 start-page: 1856 year: 2016 end-page: 1867 ident: b0125 article-title: Nivolumab for recurrent squamous-cell carcinoma of the head and neck publication-title: N Engl J Med contributor: fullname: Fayette – volume: 6 start-page: 157 year: 2007 end-page: 163 ident: b0100 article-title: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers–preliminary results publication-title: Brachytherapy contributor: fullname: Zaider – volume: 95 start-page: 386 year: 2016 end-page: 395 ident: b0050 article-title: Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Scher – volume: 104 start-page: 91 year: 2012 end-page: 95 ident: b0150 article-title: Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer publication-title: Radiother Oncol contributor: fullname: Ferris – volume: 394 start-page: 1915 year: 2019 end-page: 1928 ident: b0135 article-title: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study publication-title: Lancet contributor: fullname: Greil – volume: 111 start-page: 382 year: 2014 end-page: 387 ident: b0065 article-title: A nomogram to predict loco-regional control after re-irradiation for head and neck cancer publication-title: Radiother Oncol contributor: fullname: Sherman – volume: 15 start-page: 283 year: 1985 end-page: 289 ident: b0115 article-title: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial publication-title: Cancer Chemother Pharmacol contributor: fullname: Dorman – volume: 32 start-page: 3858 year: 2014 end-page: 3866 ident: b0015 article-title: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity publication-title: J Clin Oncol contributor: fullname: Ang – volume: 10 start-page: 425 year: 2018 end-page: 430 ident: b0110 article-title: High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option publication-title: J Contemp Brachyther contributor: fullname: Chandra – start-page: 156 year: 2016 ident: b0145 article-title: Association of Notch4 with metastasis in human oral squamous cell carcinoma publication-title: Life Sci contributor: fullname: Devi – volume: 100 year: 2018 ident: b0025 article-title: A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Caudell – volume: 13 start-page: 70 year: 2021 end-page: 80 ident: b0045 article-title: Proton therapy in head and neck cancer treatment: state of the problem and development prospects (Review) publication-title: Sovrem Tekhnologii Med contributor: fullname: Gulidov – volume: 26 start-page: 5518 year: 2008 end-page: 5523 ident: b0070 article-title: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma publication-title: J Clin Oncol contributor: fullname: Benhamou – year: 2023 ident: b0120 article-title: Prevalence of locoregional recurrence and survival post-treatment of head and neck cancers in Africa: a systematic review and meta-analysis publication-title: EClinicalMedicine contributor: fullname: Oyedele – volume: 130 year: 2016 ident: b0035 article-title: Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines publication-title: J Laryngol Otol contributor: fullname: Ahmed – volume: 20 year: 2022 ident: b0080 article-title: Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review publication-title: J Transl Med contributor: fullname: Wang – volume: 6 year: 2023 ident: b0060 article-title: Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carcinoma publication-title: JAMA Netw Open contributor: fullname: Mahfouz – volume: 9 start-page: 1421 year: 2009 end-page: 1428 ident: b0130 article-title: Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial publication-title: Expert Rev Anticancer Ther contributor: fullname: Gutiérrez-Sanz – volume: 10 year: 2018 ident: b0085 article-title: The current role of salvage surgery in recurrent head and neck squamous cell carcinoma publication-title: Cancers (Basel) contributor: fullname: Suarez – volume: 31 start-page: 845 year: 2013 end-page: 852 ident: b0010 article-title: Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer publication-title: J Clin Oncol contributor: fullname: Weber – volume: 8 year: 2021 ident: b0040 article-title: A systematic review on re-irradiation with charged particle beam therapy in the management of locally recurrent skull base and head and neck tumors publication-title: Int J Part Ther contributor: fullname: McGee – volume: 8 year: 2013 ident: b0075 article-title: Effectiveness and toxicities of intensity-modulated radiotherapy for patients with locally recurrent nasopharyngeal carcinoma publication-title: PLoS One contributor: fullname: Bai – volume: 37 year: 2015 ident: b0020 article-title: Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate publication-title: Head Neck contributor: fullname: Eisbruch – volume: 393 start-page: 40 year: 2019 end-page: 50 ident: b0005 article-title: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial publication-title: Lancet contributor: fullname: Harris – volume: 113 start-page: 759 year: 2022 end-page: 786 ident: b0030 article-title: Retreatment of recurrent or second primary head and neck cancer after prior radiation: executive summary of the American Radium Society Appropriate Use Criteria publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Bakst |
SSID | ssj0005150 |
Score | 2.4794285 |
Snippet | •Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is clinically challenging.•Methods to better select patients for re-RT is of paramount... Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for... INTRODUCTIONRe-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT)... |
SourceID | proquest pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 106875 |
SubjectTerms | Adult Aged Aged, 80 and over Female Genomics Genomics - methods Head and Neck Neoplasms - genetics Head and Neck Neoplasms - radiotherapy Humans Male Middle Aged Mutation Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - radiotherapy Pencil beam scanning Proton therapy Proton Therapy - adverse effects Proton Therapy - methods Re-Irradiation - methods Recurrent head and neck cancer Retrospective Studies Toxicity Treatment Outcome |
Title | Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer |
URI | https://dx.doi.org/10.1016/j.oraloncology.2024.106875 https://www.ncbi.nlm.nih.gov/pubmed/38824813 https://www.proquest.com/docview/3064143540 |
Volume | 154 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0hkGgvFdAPtlDkSr2mG8d2kj30gKBooQJVapG4Wf6UlpYEZXcPXPjtnYkTaXvoqcd8WEn8rPGb-M0zwCdhAvLwgNlJ6VUmFTfZrHASAXHG5tLYyKl2-PqmnN_Kqzt1twVnYy0MySqH2J9ieh-thzPToTenj4vF9AcXZY3plSIVJNIQcvyUKqddDD4_b8g8uEqVwmWd0d2j8Wiv8aIi-Lbp7aGfMFcsJF4oe83hxsz0L-bZz0AXe_BqoI7sNL3dPmyF5gBenJPch3ZsO4Dd62Gh_DX8_t61yOpYKq96Yl3IFl1HPgQEBGvXK_zgsGSm8YxsWh8WjvVVv6SHYm1kg9_qktGPWmzuko8Tw9jt-1ZNcL-YozHTvYHbi68_z-bZsLFC5gTnq0zGQglvRQyVKWNlogkij0hgZ9EXylTWW5y582iVRfri86C8iraq3WxW2dxV4i1sN20TDoEZF10ovClsQKJQhtpHTpZquXeVi7yYwJexJ_VfuGoM2XqUmN3rTSQ0IaETEhP4OHa_xoFPqxmmCe16qSl1IrIn8wm8S7jox-TQoQXmDbLm4v1_Pv0IXtJRkucew_aqW4cPSEJW9qQfZSewc3r5bX7zB8mZ4Ko |
link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VItFeEJRHl_IwEtewcWwn2UMPqFAt0K2QaKXeLD-lLW1SZXcPvfDbmYkTaTlw4hrHSjIzGn8Tf_MZ4IMwAXF4wOqk9CqTiptsVjiJDnHG5tLYyKl3eHFezi_ltyt1tQMnYy8M0SqH3J9yep-thyvTwZrTu-Vy-pOLssbyShELEmGIeAAPpUL0i0H98fcWz4Or1Cpc1hndPiqP9iQv6oJvm14f-h6LxULiQNmTDreWpn9Bz34JOn0CjwfsyD6l13sKO6E5gL3PxPehI9sO4NFi2Cl_Bjc_uhZhHUv9VfesC9my60iIgDzB2s0avzismGk8I53W26VjfdsvEaJYG9kguLpi9KcWp7sk5MQweft-VhPcL-YoaLrncHn65eJkng0nK2ROcL7OZCyU8FbEUJkyViaaIPKICHYWfaFMZb3FpTuPVlnELz4Pyqtoq9rNZpXNXSVewG7TNuEQmHHRhcKbwgZECmWofeSkqZZ7V7nIiwkcj5bUfzlWY87WI8fsWm97QpMndPLEBN6P5tcY-bSdYZrQblaaaidCezKfwMvkF32XJDq0wMJB1ly8-s-nv4O9-cXiTJ99Pf9-BPs0kri6r2F33W3CG0Qka_u2j7g_JsfiRw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton+therapy+re-irradiation+outcomes+and+genomic+landscape+of+patients+with+recurrent+head+and+neck+cancer&rft.jtitle=Oral+oncology&rft.au=Krc%2C+Rebecca&rft.au=Mendes%2C+William&rft.au=Molitoris%2C+Jason&rft.au=Ferris%2C+Matthew&rft.date=2024-07-01&rft.eissn=1879-0593&rft.volume=154&rft.spage=106875&rft.epage=106875&rft_id=info:doi/10.1016%2Fj.oraloncology.2024.106875&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1368-8375&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1368-8375&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1368-8375&client=summon |